Zejula, GlaxoSmithKline (GSK) oral PARP inhibitor, is approved in the United States and Europe for women with recurrent ovarian cancer. MNG Tracker report title “Zejula Drug Sales & Forecast” provides historical as well as estimated Zejula sales in Global market. This is single page report which also covered key factors for the growth/decline of the Zejula sales in Global market.
Confirm All Clear!
Do You Realy want to delete all items from you CART?